Search

Your search keyword '"Parolin, Veronica"' showing total 24 results
Start Over Author "Parolin, Veronica"
24 results on '"Parolin, Veronica"'

1. Predictive and prognostic effect of computed tomography–derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer

Author

Trestini, Ilaria, Caldart, Alberto, Cintoni, Marco, Sperduti, Isabella, Drudi, Alessandro, Aluffi, Gregorio, Fiorio, Elena, Parolin, Veronica, Zambonin, Valentina, Zanelli, Sara, Tregnago, Daniela, Avancini, Alice, Pilotto, Sara, Aprili, Irene, Zandonà, Emanuela, D'Onofrio, Mirko, Mele, Maria Cristina, Gasbarrini, Antonio, Scambia, Giovanni, Tortora, Giampaolo, Milella, Michele, Bria, Emilio, and Carbognin, Luisa

Published
2023
Full Text
View/download PDF

3. Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study

Author

Trestini, Ilaria, Sperduti, Isabella, Caldart, Alberto, Bonaiuto, Clelia, Fiorio, Elena, Parolin, Veronica, Zambonin, Valentina, Zanelli, Sara, Tregnago, Daniela, Avancini, Alice, Cintoni, Marco, Pilotto, Sara, Mele, Maria Cristina, Gasbarrini, Antonio, Scambia, Giovanni, Milella, Michele, Tortora, Giampaolo, Bria, Emilio, and Carbognin, Luisa

Published
2021
Full Text
View/download PDF

4. Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic

Author

Zuliani, Serena, Zampiva, Ilaria, Tregnago, Daniela, Casali, Miriam, Cavaliere, Alessandro, Fumagalli, Arianna, Merler, Sara, Riva, Silvia Teresa, Rossi, Alice, Zacchi, Francesca, Zaninotto, Elisa, Auriemma, Alessandra, Pavarana, Michele, Soldà, Caterina, Benini, Lavinia, Borghesani, Michele, Caldart, Alberto, Casalino, Simona, Gaule, Marina, Kadrija, Dzenete, Mongillo, Marta, Pesoni, Camilla, Biondani, Pamela, Cingarlini, Sara, Fiorio, Elena, Melisi, Davide, Parolin, Veronica, Tondulli, Luca, Belluomini, Lorenzo, Zecchetto, Camilla, Avesani, Barbara, Biasi, Assunta, Bovo, Chiara, Dazzani, Elena, Dodi, Alessandra, Gelmini, Sara, Leta, Luigi Carmine, Lo Cascio, Giuliana, Lombardo, Fiorella, Lucin, Eleonora, Martinelli, Ilaria Asja, Messineo, Luisa, Moscarda, Viola, Pafumi, Sarah, Reni, Anna, Sartori, Giulia, Scaglione, Ilaria Mariangela, Shoval, Yiftach, Sposito, Marco, Tacconelli, Evelina, Trestini, Ilaria, Zambonin, Valentina, Zanelli, Sara, Pilotto, Sara, and Milella, Michele

Published
2020
Full Text
View/download PDF

5. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel

Author

Lorusso, Domenica, Bologna, Alessandra, Cecere, Sabrina Chiara, De Matteis, Elisabetta, Scandurra, Giusy, Zamagni, Claudio, Arcangeli, Valentina, Artioli, Fabrizio, Bella, Mariangela, Blanco, Giusi, Cardalesi, Cinzia, Casartelli, Clelia, De Vivo, Rocco, Di Napoli, Marilena, Gisone, Emanuele Baldo, Lauria, Rossella, Lissoni, Alberto Andrea, Loizzi, Vera, Maccaroni, Elena, Mangili, Giorgia, Marchetti, Claudia, Martella, Francesca, Naglieri, Emanuele, Parolin, Veronica, Ricciardi, Giusy, Ronzino, Graziana, Salutari, Vanda, Scarfone, Giovanna, Secondino, Simona, Spagnoletti, Ilaria, Tasca, Giulia, Tognon, Germana, and Guarneri, Valentina

Published
2020
Full Text
View/download PDF

6. Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation

Author

Carbognin, Luisa, Sperduti, Isabella, Fabi, Alessandra, Dieci, Maria Vittoria, Kadrija, Dzenete, Griguolo, Gaia, Pilotto, Sara, Guarneri, Valentina, Zampiva, Ilaria, Brunelli, Matteo, Orvieto, Enrico, Nortilli, Rolando, Fiorio, Elena, Parolin, Veronica, Manfrin, Erminia, Caliò, Anna, Nisticò, Cecilia, Pellini, Francesca, Scarpa, Aldo, Pollini, Giovanni Paolo, Conte, Pierfranco, Tortora, Giampaolo, and Bria, Emilio

Published
2017
Full Text
View/download PDF

7. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, De Placido, Sabino, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Published
2020
Full Text
View/download PDF

8. Evidence-Based Tailored Nutrition Educational Intervention Improves Adherence to Dietary Guidelines, Anthropometric Measures and Serum Metabolic Biomarkers In Early-Stage Breast Cancer Patients: A Prospective Interventional Study.

Author

Trestini, Ilaria, primary, Sperduti, Isabella, additional, Caldart, Alberto, additional, Bonaiuto, Clelia, additional, Fiorio, Elena, additional, Parolin, Veronica, additional, Zambonin, Valentina, additional, Zanelli, Sara, additional, Tregnago, Daniela, additional, Avancini, Alice, additional, Cintoni, Marco, additional, Pilotto, Sara, additional, Mele, Maria Cristina, additional, Gasbarrini, Antonio, additional, Scambia, Giovanni, additional, Milella, Michele, additional, Tortora, Giampaolo, additional, Bria, Emilio, additional, and Carbognin, Luisa, additional

Published
2021
Full Text
View/download PDF

9. EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, primary, Cinieri, Saverio, additional, Berardi, Rossana, additional, Pedersini, Rebecca, additional, McCartney, Amelia, additional, Minisini, Alessandro Marco, additional, Caremoli, Elena Rota, additional, Spazzapan, Simon, additional, Magnolfi, Emanuela, additional, Brunello, Antonella, additional, Risi, Emanuela, additional, Palumbo, Raffaella, additional, Leo, Silvana, additional, Colleoni, Marco, additional, Donati, Sara, additional, De Placido, Sabino, additional, Orlando, Laura, additional, Pistelli, Mirco, additional, Parolin, Veronica, additional, Mislang, Anna, additional, Becheri, Dimitri, additional, Puglisi, Fabio, additional, Sanna, Giuseppina, additional, Zafarana, Elena, additional, Boni, Luca, additional, and Mottino, Giuseppe, additional

Published
2020
Full Text
View/download PDF

10. Effect of evidence-based nutrition educational intervention on adherence to dietary guidelines (ADG) and weight management among early-stage breast cancer (EBC) patients (pts): A prospective trial.

Author

Trestini, Ilaria, primary, Sperduti, Isabella, additional, Caldart, Alberto, additional, Bonaiuto, Clelia, additional, Fiorio, Elena, additional, Parolin, Veronica, additional, Tregnago, Daniela, additional, Avancini, Alice, additional, Pilotto, Sara, additional, Lanza, Massimo, additional, Scambia, Giovanni, additional, Tortora, Giampaolo, additional, Milella, Michele, additional, Bria, Emilio, additional, and Carbognin, Luisa, additional

Published
2020
Full Text
View/download PDF

11. Additional file 2 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, Placido, Sabino De, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Abstract

Additional File 2: Supplementary Table 2 (S2). Distribution of CTCAE G2-3 fatigue and neurotoxicity by age and arm of treatment. Reported as N (%) unless otherwise indicated. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events.

Published
2020
Full Text
View/download PDF

12. Additional file 1 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, McCartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, Placido, Sabino De, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Abstract

Additional File 1: Supplementary Table 1 (S1). Distribution of AEs by arm in patients aged ≥75 years. Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; /, grade does not exist for this adverse event; ° grade 5 n=1.

Published
2020
Full Text
View/download PDF

13. Prospective trial in early-stage breast cancer (EBC) patients (pts) submitted to nutrition evidence-based educational intervention: Early results of adherence to dietary guidelines (ADG) and body weight change (BWC).

Author

Carbognin, Luisa, primary, Trestini, Ilaria, additional, Sperduti, Isabella, additional, Bonaiuto, Clelia, additional, Zambonin, Valentina, additional, Fiorio, Elena, additional, Tregnago, Daniela, additional, Parolin, Veronica, additional, Pilotto, Sara, additional, Scambia, Giovanni, additional, Tortora, Giampaolo, additional, Milella, Michele, additional, and Bria, Emilio, additional

Published
2019
Full Text
View/download PDF

14. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis

Author

Molino Annamaria, Auriemma Alessandra, Remo Andrea, Micciolo Rocco, Terrasi Marianna, Mercanti Anna, Fiorio Elena, Parolin Veronica, Di Stefano Bruno, Bonetti Franco, Giordano Antonio, Cetto Gian, and Surmacz Eva

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Obesity in postmenopausal women is associated with increased breast cancer risk, development of more aggressive tumors and resistance to certain anti-breast cancer treatments. Some of these effects might be mediated by obesity hormone leptin, acting independently or modulating other signaling pathways. Here we focused on the link between leptin and HER2. We tested if HER2 and the leptin receptor (ObR) can be coexpressed in breast cancer cell models, whether these two receptors can physically interact, and whether leptin can transactivate HER2. Next, we studied if leptin/ObR can coexist with HER2 in breast cancer tissues, and if presence of these two systems correlates with specific clinicopathological features. Methods Expression of ObR, HER2, phospo-HER2 was assessed by immonoblotting. Physical interactions between ObR and HER2 were probed by immunoprecipitation and fluorescent immunostaining. Expression of leptin and ObR in breast cancer tissues was detected by immunohistochemistry (IHC). Associations among markers studied by IHC were evaluated using Fisher's exact test for count data. Results HER2 and ObR were coexpressed in all studied breast cancer cell lines. In MCF-7 cells, HER2 physically interacted with ObR and leptin treatment increased HER2 phosphorylation on Tyr 1248. In 59 breast cancers, the presence of leptin was correlated with ObR (the overall association was about 93%). This result was confirmed both in HER2-positive and in HER2-negative subgroups. The expression of leptin or ObR was numerically more frequent in larger (> 10 mm) tumors. Conclusion Coexpression of HER2 and the leptin/ObR system might contribute to enhanced HER2 activity and reduced sensitivity to anti-HER2 treatments.

Published
2008
Full Text
View/download PDF

16. A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).

Author

Carbognin, Luisa, primary, Sperduti, Isabella, additional, Arpino, Grazia, additional, Dieci, Maria Vittoria, additional, Schettini, Francesco, additional, Griguolo, Gaia, additional, Guarneri, Valentina, additional, Brunelli, Matteo, additional, Nortilli, Rolando, additional, Fiorio, Elena, additional, Parolin, Veronica, additional, Pilotto, Sara, additional, Orvieto, Enrico, additional, Manfrin, Erminia, additional, Pellini, Francesca, additional, Pollini, Giovanni Paolo, additional, Conte, Pier Franco, additional, De Placido, Sabino, additional, Tortora, Giampaolo, additional, and Bria, Emilio, additional

Published
2017
Full Text
View/download PDF

17. Clinical results of randomized trials and ‘real-world’ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

Author

Zambonin, Valentina, primary, De Toma, Alessandro, additional, Carbognin, Luisa, additional, Nortilli, Rolando, additional, Fiorio, Elena, additional, Parolin, Veronica, additional, Pilotto, Sara, additional, Cuppone, Federica, additional, Pellini, Francesca, additional, Lombardi, Davide, additional, Pollini, Giovanni Paolo, additional, Tortora, Giampaolo, additional, and Bria, Emilio, additional

Published
2017
Full Text
View/download PDF

18. Effect of Acceptance and Commitment Therapy (ACT) on Weight Loss and the Acceptance of Body Image in Breast Cancer Patients. In: Abstracts of the IPOS 15th World Congress of Psycho-Oncology. November 4-8, 2013. Rotterdam, The Netherlands

Author

Deledda, Giuseppe, Mandragona, Roberta, Barutti, C, Goss, Claudia, DEL PICCOLO, Lidia, Bissoli, Luisa, Fiorio, Elena, Lenotti, M, Filippi, E, Parolin, Veronica, Ballarin, M, Mazzi, Maria Angela, Nalini, A, Zamboni, Mauro, and Molino, Annamaria

Subjects
Acceptance and Commitment Therapy (ACT), BMI, Acceptance and Commitment Therapy (ACT), BMI, Breast Cancer Patients, Breast Cancer Patients
Published
2013

19. Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.

Author

Kadrija, Dzenete, Pilotto, Sara, Zampiva, Ilaria, Carbognin, Luisa, Nortilli, Rolando, Fiorio, Elena, Parolin, Veronica, Tortora, Giampaolo, Bria, Emilio, Brunelli, Matteo, Manfrin, Erminia, Caliò, Anna, Scarpa, Aldo, Pellini, Francesca, Pollini, Giovanni Paolo, Sperduti, Isabella, Fabi, Alessandra, Nisticò, Cecilia, Dieci, Maria Vittoria, and Griguolo, Gaia

Subjects
LOBULAR carcinoma, KI-67 antigen, CANCER cell proliferation, BREAST cancer prognosis, BIOMARKERS, HISTOPATHOLOGY, PROGRESSION-free survival, BREAST cancer surgery, PROGNOSIS
Abstract

Introduction The intent of this analysis was to investigate and validate the prognostic potential of Ki67 in a multi-center series of patients affected by early stage ‘pure’ invasive lobular carcinoma (ILC). Methods Clinical-pathological data of patients affected by ILC were correlated with overall survival and disease-free survival (OS/DFS); data from a parallel invasive ductal carcinoma (IDC) patients' cohort were gathered as well. The maximally selected Log-Rank statistics analysis was applied to Ki67 continuous variable to estimate the appropriate cut-off. The Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was performed as well. Results Data from overall 1097 (457/222 ILC: training/validation set; 418 IDC) patients were gathered. The identified optimal Ki67 cut-offs were 4% and 14% for DFS in ILC and IDC cohort, respectively. In ILC patients, the Ki67 cut-off was an independent OS predictor. Ten-years OS and DFS were 89.9% and 77.2% ( p = 0.007 ) and 79.4% and 69.2% ( p = 0.03 ) for patients with Ki67 ≤ 4% and >4%, respectively. In IDC patients, 10-years OS was 93.8% and 71.7%, p = 0.02, DFS was 84.0% and 52.6%, p = 0.0003 , for patients with Ki67 ≤ 14% and >14%, respectively. In the validation set, the optimal Ki67 OS cut-off was 5%. The STEPP analysis showed that in the presence of low Ki67 values, IDC patients have a better DFS than ILC patients, while with the increase of values the prognosis tends to overlap. Conclusions Despite the retrospective design of the study, the prognostic relevance of Ki67 (as well as its optimal cut-off) seems to significantly differ according to breast cancer histology. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

20. Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2- metastatic breast cancer (mBC).

Author

Avesani, Barbara, Giontella, Elena, Caldart, Alberto, De Noni, Alessandro, Muzzarelli, Alice, Borghesani, Giulia, Insolda, Jessica, Biondani, Pamela, Parolin, Veronica, Pellini, Francesca, Scarpa, Aldo, Nottegar, Alessia, Lawlor, Rita T, Mafficini, Andrea, Paris, Ida, Minucci, Angelo, Pasciuto, Tina, Fabi, Alessandra, Fiorio, Elena, and Milella, Michele

Published
2023
Full Text
View/download PDF

22. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysis

Author

Fiorio, Elena, primary, Mercanti, Anna, additional, Terrasi, Marianna, additional, Micciolo, Rocco, additional, Remo, Andrea, additional, Auriemma, Alessandra, additional, Molino, Annamaria, additional, Parolin, Veronica, additional, Di Stefano, Bruno, additional, Bonetti, Franco, additional, Giordano, Antonio, additional, Cetto, Gian Luigi, additional, and Surmacz, Eva, additional

Published
2008
Full Text
View/download PDF

23. The effect trial: A randomized phase II trial evaluating two different doses of weekly (W) NAB-paclitaxel (NP) as first-line chemotherapy in older breast cancer (BC) patients (pts)

Author

Biganzoli, Laura, Berardi, Rossana, Pedersini, Rebecca, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Lima, Julianne Silva, Baldari, Daniela, Orlando, Laura, Magnolfi, Emanuela, Pistelli, Mirco, Brunello, Antonella, Zafarana, Elena, ANTONIO BERNARDO, Leo, Silvana, Colleoni, Marco, Donati, Sara, Placido, Sabino, Parolin, Veronica, Vitale, Stefania, Di Leo, Angelo, Puglisi, Fabio, Boni, Luca, and Cinieri, Saverio

24. EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Antonella Brunello, Silvana Leo, Emanuela Magnolfi, Sabino De Placido, Raffaella Palumbo, Alessandro Marco Minisini, Elena Rota Caremoli, Elena Zafarana, Sara Donati, Emanuela Risi, Anna Rachelle Mislang, Giuseppe Mottino, Luca Boni, Dimitri Becheri, Rossana Berardi, Mirco Pistelli, Fabio Puglisi, Amelia McCartney, Rebecca Pedersini, Laura Biganzoli, Veronica Parolin, Simon Spazzapan, Giuseppina Sanna, Saverio Cinieri, Marco Colleoni, Laura Orlando, Biganzoli, Laura, Cinieri, Saverio, Berardi, Rossana, Pedersini, Rebecca, Mccartney, Amelia, Minisini, Alessandro Marco, Caremoli, Elena Rota, Spazzapan, Simon, Magnolfi, Emanuela, Brunello, Antonella, Risi, Emanuela, Palumbo, Raffaella, Leo, Silvana, Colleoni, Marco, Donati, Sara, De Placido, Sabino, Orlando, Laura, Pistelli, Mirco, Parolin, Veronica, Mislang, Anna, Becheri, Dimitri, Puglisi, Fabio, Sanna, Giuseppina, Zafarana, Elena, Boni, Luca, and Mottino, Giuseppe

Subjects
Phases of clinical research, law.invention, Efficacy, 0302 clinical medicine, Breast cancer, Randomized controlled trial, law, Functional decline, Clinical endpoint, Age Factor, Older adult, Aged, 80 and over, Age Factors, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Rate, 030220 oncology & carcinogenesis, Older adults, Metastatic, Female, Breast Neoplasm, Research Article, Human, medicine.medical_specialty, Paclitaxel, Prognosi, Breast Neoplasms, Nab-paclitaxel, lcsh:RC254-282, 03 medical and health sciences, Albumins, Internal medicine, medicine, Humans, Neoplasm Invasiveness, Progression-free survival, Adverse effect, Survival rate, Aged, Neoplasm Staging, Neoplasm Invasivene, Dose-Response Relationship, Drug, Toxicity, business.industry, Albumin, medicine.disease, Antineoplastic Agents, Phytogenic, business
Abstract

Background Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population. Methods EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m2 (arm A) or 125 mg/m2 (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatment for advanced disease. The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD), or death. In each arm, the null hypothesis that the median EFS would be ≤ 7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS was 8.2 months (90% CI, 5.9–8.9; p = 0.188) in arm A vs 8.3 months (90% CI, 6.2–9.7, p = 0.078) in arm B. Progression-free survival, overall survival, and response rates were similar in both groups. A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B. The most frequently reported non-haematological AEs were fatigue (grade [G] 2–3 toxicity occurrence in arm A vs B, 43% and 51%, respectively) and peripheral neuropathy (G2–3 arm A vs B, 19% and 38%, respectively). Conclusion Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m2 was significantly better tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older patients with advanced disease. Trial registration EudraCT, 2012-002707-18. Registered on June 4, 2012. NIH ClinicalTrials.gov, NCT02783222. Retrospectively registered on May 26, 2016.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results